MedTrace Logo

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.

NCT01219348 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2015-08-18

No results posted yet for this study

Summary

Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.

Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

Conditions

Interventions

BIOLOGICAL

IDO peptide vaccination

Vaccination every second week

Sponsors & Collaborators

  • Inge Marie Svane

    lead OTHER

Principal Investigators

  • Trine Zeeberg Iversen, MD · Center for Cancer Immune Therapy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219348 on ClinicalTrials.gov